Delivery Order SPE2DB24D2205-SPE2DB25FEHSB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $36,245.57 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order was placed under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on...
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $148,306.62 and an ultimate completion date of September 3, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $5,533.31 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $51,174.08 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30, with a firm fixed price structure and an ultimate completion date of September 16, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending...
- The Defense Logistics Agency awarded a $46,648.39 delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price contract with a completion date of June 17, 2025, and represents a non-set-aside award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order is...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitive award carries a ceiling value of $66,334.24 under a firm fixed-price contract type with an ultimate completion date of September 9, 2025. The award was not designated as a set-aside contract, reflecting open competition among qualified vendors. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,714.12 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, and represents a competitively awarded procurement. The contract was executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $33,016.79 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price contract represents a non-compete award and is performed at the awardee's location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationship with the...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHSBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $39,217.65 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on September 17, 2025, with completion targeted for September 18, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation, reflecting open competition among qualified pharmaceutical distributors. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order exemplifies the company's role in supplying brand-name medications across multiple therapeutic domains to the Defense Health Agency and related federal healthcare entities. The SPE2DX vehicle enables AmerisourceBergen to provide comprehensive pharmaceutical support globally, with the DLA planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional awards across several contractors to optimize medical supply chain efficiency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.2k | 9/17/25 |